<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Pectasides, D.</style></author><author><style face="normal" font="default" size="100%">Fountzilas, G.</style></author><author><style face="normal" font="default" size="100%">Aravantinos, G.</style></author><author><style face="normal" font="default" size="100%">Kalofonos, H.P.</style></author><author><style face="normal" font="default" size="100%">Efstathiou, E.</style></author><author><style face="normal" font="default" size="100%">Salamalekis, E.</style></author><author><style face="normal" font="default" size="100%">Farmakis, D.</style></author><author><style face="normal" font="default" size="100%">Skarlos, D.</style></author><author><style face="normal" font="default" size="100%">Briasoulis, E.</style></author><author><style face="normal" font="default" size="100%">Economopoulos, T.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Advanced stage mucinous epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience</style></title><secondary-title><style face="normal" font="default" size="100%">Gynecologic Oncology</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Mucinous epithelial ovarian cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">Platinum-based chemotherapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Response</style></keyword><keyword><style  face="normal" font="default" size="100%">Survival</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2005</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2005</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-20944439079&amp;doi=10.1016%2fj.ygyno.2004.12.056&amp;partnerID=40&amp;md5=b8b8d79d0411f30f7e80854de0c63994</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">97</style></volume><pages><style face="normal" font="default" size="100%">436 - 441</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Objective. Mucinous epithelial ovarian cancer (mEOC) representing about 10% of all EOC are known to be possibly resistant to platinum-based chemotherapy and bear a poorer prognosis with respect to other subtypes of EOC. This study was undertaken to compare response and survival to platinum-based chemotherapy between patients with advanced stages III and IV mEOC and serous EOC (sEOC). Methods. A retrospective analysis was performed in 47 patients with advanced stage of mEOC treated with first-line platinum-based chemotherapy in the context of several study protocols of the Hellenic Cooperative Oncology Group (HeCOG) between 6/7/1983 and 25/2/2003. The outcome was compared to that of 94 patients with sEOC treated with the same protocols during the same study period (ratio mucinous: serous 1:2). Results. One hundred forty-one patients (47 stages III and IV mEOC, 94 stages III and IV sEOC) treated with platinum-based chemotherapy were analyzed. The overall response rate for mEOC was 38.5% (complete remission 18%) (95% CI 23.4-55.4%) and 70% (complete remission 47%) (95% CI 58.5-80.3%) for sEOC (P = 0.001). After a median follow-up of 77.8 months, median survival and time to tumor progression (TTP) were not significantly different between the two groups (33.2 months [95% CI 23.3-43.1 months] vs. 38.0 months [95% CI 26.8-49.2 months], P = 0.46, 11.8 months [95% CI 7.2-16.4 months] vs. 20.0 months [95% CI 15.7-24.2 months], P = 0.18, respectively). Conclusion. Patients with mEOC have significantly lower response to first-line platinum-based chemotherapy compared to patients with sEOC. This low response to platinum-based chemotherapy was not translated in inferior TTP or survival. Our data indicate that a new strategy for chemotherapy in mEOC should be adopted, one that focuses on new agents without cross-resistance to platinum agents. © 2005 Elsevier Inc. All rights reserved.</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><notes><style face="normal" font="default" size="100%">Cited By :49Export Date: 21 February 2017</style></notes></record></records></xml>